MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwired - April 16, 2013) -
Securities Code Numbers: 663200 and A1RFJ5
ISIN: DE0006632003 and DE000A1RFJ5
The text decisive for the invitation to the Annual General Meeting of
AG is the one written in the German language.
Invitation to the Annual General Meeting 2013 of MorphoSys AG
We hereby invite the shareholders of our Company to the Annual General
which is taking place on June 4, 2013 at 10:00 a.m., in the Conference
Munich, Hanns-Seidel-Stiftung, Lazarettstraße 33, 80636 Munich.
1. Presentation of the adopted financial statements and the approved
consolidated financial statements as of December 31, 2012, the
reports including the report of the Supervisory Board for the financial
2012 and the explanatory report of the Management Board regarding the
disclosures pursuant to sec.s 289 para. 4, 315 para. 4 German
2. Resolution on the use of the accumulated profit of MorphoSys AG for the
financial year 2012
3. Resolution on the formal approval of the activities of the members of
Management Board in respect of the financial year 2012
4. Resolution on the formal approval of the activities of the members of
Supervisory Board in respect of the financial year 2012
5. Resolution on the appointment of the auditor for the financial year
6. Resolution on the amendment of the authorization to issue convertible
based on the resolution of the Annual General Meeting on May 14, 2008
the corresponding provision of the Articles of Association to avoid
with a deviating entitlement to dividend
7. Resolution on the creation of a new Authorized Capital 2013-I with the
possibility to exclude pre-emptive rights of the shareholders;
the Articles of Association
Please find the full text of the invitation here: www.morphosys.com/agm
MorphoSys developed HuCAL, the most successful antibody library
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
Ylanthia® and 100 billion high potentials® are registered
Slonomics® is a registered trademark of Sloning BioTechnology
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE